MDS Nordion Submits Expression of Interest Proposal to Government of Canada on Medical Isotope and Generator Production
MAPLE Reactors Could Solve the Isotope Crisis within 24 months
With no domestic or international sources of supply that can fully mitigate the current global shortage of medical isotopes, MDS Nordion urges Atomic Energy of Canada Limited (AECL) to complete the MAPLE project to address this shortage. With expertise and guidance from the South African Nuclear Energy Corporation (Necsa), owner and operator of the SAFARI-1 reactor, and working with AECL, MDS Nordion believes a solution could be achieved in an estimated 24 months.
“MDS Nordion is a solutions oriented Company with strong technical and regulatory expertise. We look forward to working with Necsa on the next stages of this proposal,” said
MDS Nordion urges AECL to honour its long-standing commitment to replace the National Research Universal (NRU) by bringing the MAPLE facilities into service. This can be done through AECL collaborating with Necsa on the adaption of the OSCAR computer codes, which are successfully used by the world’s leading isotope producing reactors. The computer codes are specifically designed to model research reactor performance and operation and are being used by the High Flux Reactor in Petten,
During the Standing Committee on Natural Resources session on
As a key collaborator in the project, “Necsa is honoured to be considered part of this important endeavour needed to secure a stable and reliable supply of Mo-99 and Tc-99m to the market by offering its comprehensive expertise in the physics and operation of material test reactors and the OSCAR system to support MDS Nordion’s project proposal” stated
In addition to the OSCAR computer codes, MDS Nordion is proposing the construction of a fully licensed production facility to manufacture Tc-99m generators for distribution to Canadian hospitals in all regions of
About MDS Nordion
MDS Nordion, a business unit of MDS Inc., is a global leader in providing medical isotopes for molecular and diagnostic imaging, radiotherapeutics and sterilization technologies for medical products that benefit the lives of millions of people in more than 50 countries around the world. MDS Nordion products and services are used on a daily basis by pharmaceutical and biotechnology companies, medical-device manufacturers, hospitals, clinics and research laboratories. Find out more at www.mdsnordion.com
MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that provides market-leading products and services that our customers need for the development of drugs, and the diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 4,200 highly skilled people in 13 countries. Find out more at www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.
SOURCE MDS Nordion